ADA	Antidrug antibody
ADC	Antibody–drug conjugate
ADME	Absorption, distribution, metabolism and excretion
CIQA	Cryo-imaging quantitative autoradiography
DAR	Drug-to-antibody ratio
DM1	Mertansine
DM4	Ravtansine
DOTA	Tetraxetan
DTPA	Pentetic acid
EIC	Extracted-ion chromatogram
ELISA	Enzyme-linked immunosorbent assay
EPR	Enhanced permeability and retention
Fab	Fragment antigen binding
Fc	Fragment crystallizable
FcRn	Neonatal Fc receptor
FDA	Food and Drug Administration
FMT	Fluorescence molecular tomography
HER-2	Human epidermal growth factor receptor 2
HR/AM	High resolution accurate-mass
HRMS	High resolution mass spectrometry
HRP	Horseradish peroxidase
IgG	Immunoglobulin G
IS	Internal standard
LBA	Ligand binding assay
LB-LC–MS	Ligand-binding immuno-affinity capture followed by LC–MS analysis
LC–MS	Liquid chromatography tandem mass spectrometry
LESA–µLC–MS	Liquid extraction surface analysis coupled to µLC–MS
LLOQ	Lower limit of quantification
MMAE	Monomethyl auristatin E
MMAF	Monomethyl auristatin F
nSMOL	Nano-surface and molecular-orientation limited proteolysis
PET	Positron emission tomography
QWBA	Quantitative whole-body autoradiography
SEC	Size exclusion chromatography
SHA	Semihomogeneous assay
SPE	Solid phase extraction
SPECT	Single-photon emission computed tomography
T-DM1	Trastuzumab emtansine/Kadcyla®